University of Wisconsin Foundation
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), University of Wisconsin Foundation reported 10 stock positions worth $112.6 million. Its top holding was Pearl Diver Credit Compy (PDCC) at 13.6% of the portfolio, followed by Nu Holdings Ltd./Cayman Isl-A (NU, 13.1%) and Vaxcyte (PCVX, 12.4%). Compared with Q4 2025, it opened 3 new positions, sold out of 1, added to 1 and reduced 5. The biggest buy was a new position in Sea Ltd.-ADR (SE) and the biggest sale Nu Holdings Ltd./Cayman Isl-A (NU, shares −28%).
- Most Recent 13F
- Q2 2026
- Location
- MADISON, WI
- CIK
- 0001697228
- Portfolio Value
- $112.6M (Q1 2026)
- SEC Filing
- 0001697228-26-000003 ↗ filed May 14, 2026
Holdings Value
Holdings 10 stocks · $112.6M
| PDCC Pearl Diver Credit Compy Inc. | 13.61% | 1,459,021 | $15.3M | No change |
| NU Nu Holdings Ltd./Cayman Isl-A filed as NU HLDGS LTD | 13.10% | 1,026,765 | $14.8M | Reduce -28.3% |
| PCVX Vaxcyte Inc. | 12.37% | 239,749 | $13.9M | Reduce -2.9% |
| AAPL Apple Inc. | 9.54% | 42,335 | $10.7M | Reduce -35.3% |
| SE Sea Ltd.-ADR | 9.46% | 128,620 | $10.7M | New |
| NVDA Nvidia Corp. | 9.29% | 60,035 | $10.5M | Reduce -32.6% |
| GOOGL Alphabet Inc. Class A | 9.14% | 35,789 | $10.3M | New |
| MSFT Microsoft Corp. | 8.49% | 25,842 | $9.6M | Reduce -20.3% |
| DYN Dyne Therapeutics Inc. | 7.80% | 484,745 | $8.8M | Add +16.3% |
| PRAX Praxis Precision Medicines I | 7.21% | 25,215 | $8.1M | New |
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $126.3M | SMH, CBRS, PDCC, PCVX, NU |
| Q1 2026 | 10 | $112.6M | PDCC, NU, PCVX, AAPL, SE |
| Q4 2025 | 8 | $118.9M | NU, PDCC, AAPL, NVDA, MSFT |
| Q3 2025 | 9 | $118.1M | PDCC, NU, AKRO, RNAM, NVDA |
| Q2 2025 | 5 | $89.4M | PDCC, NU, AKRO, MDGL, ETNB |
| Q1 2025 | 8 | $117.8M | SE, PDCC, MDGL, NU, AKRO |
| Q4 2024 | 7 | $137.6M | SE, PDCC, IVV, NU, MDGL |
| Q3 2024 | 7 | $153.3M | SE, IVV, PDCC, NU, AKRO |
| Q2 2024 | 6 | $88.8M | IVV, NU, MDGL, GE, AKRO |
| Q1 2024 | 6 | $88.6M | IVV, NU, MDGL, GE, AKRO |